Recent Material Events - Acusphere, Inc (ACUS)

Filing Date	Description
2008-09-02	On August 26, 2008, Acusphere, Inc. (the “Company”) received notice from holders of shares of its 6 1/2% convertible exchangeable preferred stock (the “Preferred Stock”) electing to convert, in the aggregate, 170,000 shares of Pre ...
2008-08-26	On August 25, 2008, the Board of Directors of the Company elected not to declare a quarterly cash dividend in the amount of $0.8125 per share on its 6.5% convertible exchangeable preferred stock (the “Preferred Stock”) that was otherwise pa ...
2008-08-13	As previously announced on August 11, 2008, Acusphere, Inc. (the “Company”) notified The NASDAQ Stock Market LLC (“NASDAQ”) that, as of June 30, 2008, the Company does not comply with the minimum stockholders’ equity requirem ...
2008-07-29	On July 29, 2008, Acusphere, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Patent License Agreement (the “Agreement”) by and between the Company and Bracco International BV (“Bracco”) ...
2008-07-28	On July 28, 2008, Acusphere, Inc. (the “Company”) eliminated 24 positions, or approximately twenty-four percent (24%) of its workforce. On July 28, 2008, the Company began notifying the affected employees. ...
2008-07-15	As previously announced, on January 10, 2008 Acusphere, Inc. (the “Company”) received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) advising it that the bid price of the Company’s common stock had closed below the mini ...
2008-06-30	On June 30, 2008, Acusphere, Inc. issued a press release announcing that the New Drug Application (NDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres for Injectable Suspension), has been accepted ...
2008-06-06	On June 5, 2008, a majority of the stockholders of Acusphere, Inc. (the “Company”) approved a proposal to grant the Company’s board of directors authority to amend the Company’s certificate of incorporation to increase the authori ...
2008-05-20	On May 15, 2008, Acusphere, Inc. (the “Company”) entered into a second amendment (the “Second BSP Amendment”) to the Patent Transfer Agreement by and between the Company and Bayer Schering Pharma AG (“BSP”) dated as of M ...
2008-04-29	On April 28, 2008, Acusphere, Inc. issued a press release announcing the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polyme ...